For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...

Huntington’s disease was long thought to be caused by the slow buildup of a toxic protein, but new research has reveale | ...

Gene therapy maker bluebird bio’s 15-year flight has landed in the nest of private equity firms Carlyle and SK Capital in a ...

AbbVie-partnered Mission Therapeutics is tweaking its trajectory, closing a preclinical laboratory in the U.K. to focus on ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.65 billion ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...

The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...

Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...

Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...